Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Encycle, Pfizer ink collaboration
December 2017
SHARING OPTIONS:

TORONTO—Encycle Therapeutics kicked off November with news of a research collaboration with Pfizer Inc. to optimize certain nacellins that act on an undisclosed therapeutic target. Pfizer identified the nacellins when it previously screened Encycle’s proprietary library. Nacellins are a kind of peptide macrocycle that often present with higher permeability, solubility and stability compared to conventional constrained peptides.
 
“We’re very pleased to continue to build our relationship with Pfizer,” said Encycle Therapeutics President and CEO Dr. Jeffrey Coull. “Unlike small molecules, nacellins can disrupt protein-protein interactions with high affinity, but unlike biologics, they can render this modulation while maintaining drug-like properties, including oral bioavailability. Considering that it is estimated that only a small proportion of the proteome is druggable using conventional therapeutics, we believe that our technology has enormous potential to underpin new therapeutic strategies.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.